Tumor necrosis factor monoclonal antibody prevents alterations in leukocyte populations during cardiopulmonary bypass

To define the role of tumor necrosis factor-α (TNF-α) on leukocyte populations during cardiopulmonary bypass (CPB), a prebypass treatment with TNF-α monoclonal murine antibody in experimental CPB in swine was used and the leukocyte response during and after CPB was measured. The leukocyte response to CPB was measured at 10, 30, 60, and 120 min during CPB and at 60 and 120 min after CPB. The experimental data suggest that TNF-α may play an important role in the early alterations in leukocyte populations associated with CPB, and TNF-α monoclonal murine antibody pretreatment ameliorates the leukocyte response.